Disease Domain | Count |
---|---|
Neoplasms | 9 |
Top 5 Drug Type | Count |
---|---|
Bispecific antibody | 5 |
Monoclonal antibody | 2 |
Unknown | 1 |
iNKT cell therapy | 1 |
CAR-NKT | 1 |
Target |
Mechanism CLDN18.2 inhibitors |
Active Org. SparX Therapeutics, Inc.Startup |
Originator Org. SparX Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CLDN18.2 inhibitors |
Active Org. SparX Therapeutics, Inc.Startup |
Originator Org. SparX Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism LILRB2 inhibitors [+1] |
Active Org. SparX Therapeutics, Inc.Startup [+1] |
Originator Org. SparX Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Mar 2024 |
Sponsor / Collaborator SparX Therapeutics, Inc.Startup |
Start Date01 Apr 2022 |
Sponsor / Collaborator SparX Therapeutics, Inc.Startup |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
SPX-303 ( LILRB2 x PDL1 ) | Colorectal Cancer More | Phase 1 |
SPX-101(SparX Biopharmaceutical) ( CLDN18.2 ) | Solid tumor More | Phase 1 |
SPX-102 ( CLDN18.2 ) | Neoplasms More | Phase 1 |
SPX-304 | Colonic Cancer More | Preclinical |
SPX-306 | Neoplasms More | Preclinical |